Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial
Methieu C et al. Diabetes Care 2018: dc180623. doi: 10.2337/dc18-0623
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.